Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q3 2023 Earnings Call Transcript

Page 5 of 5

Dr. Al Sandrock: Is this on our tau knockdown or tau…

Divya Rao: Yes, VY-TAU01 program, with the IND…

Dr. Al Sandrock: We’ve already selected a development candidate. And so we’re in the process of — we just initiated the GLP toxicology studies. We have started the manufacturing. Obviously, you have to manufacture enough material to do the GLP tox studies. And if we want to start clinical trials shortly after we file an IND the first half of next year, we have to have enough product to be able to do the first in human clinical studies, and we’re on track for all that. Does that answer your question?

Divya Rao: Yes, it does. Thank you so much.

Operator: Thank you. And I see no further questions in the queue at this time. I will now turn the call back over to Dr. Al Sandrock for any closing remarks.

Dr. Al Sandrock: Thank you to everyone for joining us today. And please feel free to follow up with us directly if you have any further questions. Thanks again.

Operator: Ladies and gentlemen, this concludes today’s presentation. Thank you once again for your participation. You may now disconnect.

Follow Voyager Therapeutics Inc. (NASDAQ:VYGR)

Page 5 of 5